NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Immuron Limited IMRN
10 fiscal years on record · AUD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
AUD 7.3M
▲ 48.6% vs FY2023
EPS · FY24
AUD -2.26
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-71.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
AUD 7.3M
Revenue, FY2024 · full 10-year series below
Revenue
Net income
The company lost 72 cents on every revenue dollar this year.
Per share
AUD -2.26
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-73.3%
Net margin-71.6%
Return on assets-40.6%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+23.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+112.0%
+23.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
AUD 10.1M
total assets, end of FY2024
Total assetsAUD 10.1M
CashAUD 2.8M
Current ratio5.09×
History
10 fiscal years
Every figure from documents filed with the SEC · AUD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue AUD B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income AUD B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA AUD B
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax AUD B
·
·
·
·
·
·
·
·
·
·
Net income AUD B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted AUD
−2.26
−3.04
−1.66
−1.25
−3.79
−1.66
·
·
·
·
Dividend / sh AUD
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
0.00
·
·
·
·
0.13
0.08
0.07
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 4 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed